MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments

MaxCyte

12/11/2025 21:26

Overview

MaxCyte Q3 revenue falls 16% yr/yr, maintaining full-year guidance

Adjusted EBITDA beats analyst expectations, reflecting effective cost management

Company expands SPL program with new agreement, adding Moonlight Bio

Outlook

MaxCyte expects 2025 core revenue to be flat to a 10% decline vs 2024

SPL Program-related revenue expected to be $5 mln for 2025

Company anticipates ending 2025 with $152 mln to $155 mln in cash and investments

Result Drivers

RESTRUCTURING - Co in the quarter announced operational restructuring to cut costs and accelerate profitability

NEW SPL CLIENTS - Co added new SPL client Moonlight Bio, expanding total SPL agreements to 32

DECREASED CORE REVENUE - Core business revenue fell 21% yr/yr due to lower sales in instruments, PAs, consumables, and licenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$12.40 mln
Q3 Adjusted EBITDA
Beat
-$10 mln
-$10.12 mln (5 Analysts)
Q3 Gross Profit
$5.20 mln
Q3 Operating Expenses
$19.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for MaxCyte Inc is $5.72, about 72.9% above its November 11 closing price of $1.55

Press Release: ID:nGNX7mKG71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)